DOCSLIB.ORG

NLM Technical Bulletin, No.117-128

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ISSN 0146 3055 "II 'Ml THE NLM TECHNICAL BULLETIN January 1979 No. 117 THE CONTENTS OF THIS PUBLICATION ARE NOT COPYRIGHTED AND MAY BE FREELY REPRODUCED TABLE OF CONTENTS Page FILES 2 TECHNICAL NOTES 3 AVLINE UPDATE 5 NEW SERIALS ANNOUNCEMENT - DECEMBER 1978 8 LIST OF MONOGRAPHS INDEXED - FEBRUARY 1979 13 PHONES LIST APPENDIX A U.S. DEPARTMENT OF HEALTH. EDUCATION. AND WELFARE Public Health Service National Institutesof Health lECHNICAL BULLETIN - JAN 79 FILES TOTAL DATES DATE LAST LATEST DATA BASE RECORDS COVERED UPDATED UPDATE TAG *AVLINE 6,703 THROUGH 1979 01 FEB 79 BACK66 501,802 JAN 66-DEC 68 11 DEC 78 BACK69 668,258 JAN 69-DEC 71 11 DEC 78 BACK72 669,109 JAN 72-DEC 74 11 DEC 78 +BACK75 642,954 JAN 75-DEC 76 11 DEC 78 *BIOETHICS 6,195 JAN 73-DEC 77 30 OCT 78 7810(EM) *CANCERLIT 152,739 JAN 63-JAN 79 25 JAN 79 7901(ED) *CANCERPROJ 21,646 1976-1978 11 JAN 79 7812(ED) *CATLINE 183,320 1965-1979 01 FEB 79 CHEMLINE 248,877 01 JUN 78 *CLINPROT 1,168 30 SEP 78 7809(ED) *EPILEPSY 24,177 1945-PRESENT 20,JAN 79 HEALTH 104,021 JAN 75-FEB 79 20 JAN 79 7902(EM) *HISTLINE 34,728 29 JAN 79 HEDLINE 412,738 JAN 77-FEB 79 08 JAN 79 7902(IN) MESH VOC 14,817 1979 11 DEC 78 *NAME AUTH 101,615 1979 31 JAN 79 *RTECS 32,603 1978 08 JAN 79 SDILINE 19,875 FEB 79 08 JAN 79 *S£RLINE 31,221 1978 30 OCT 78 *TDB 2,482 30 OCT 78 *TQXLINE 541,449 29 JAN 79 7901(ST) CBAC 276,756 1974-VOL 28(12); VOL 29(1) TOXBIB 107,051 1974-FEB 79 IPA 30,696 1974-OCT-NOV 78 HEEP 68,144 1974-FEB 79 PESTAB 15,075 1974-JAN 79 EHIC 19,093 1960-1977 ETIC 11,600 1950-JUL 78 *TOXBACK 379,299 06 FEB 78 CBAC 167,668 1965-1973 TOXBIB 127,104 1968-1973 IPA 19,188 1970-1973 HEEP 24,680 1971-1973 HAPAB 12,816 1966-1973 HAYES 10,043 1940-1966 TMIC 4,552 1971-1975 TERA 13,248 1960-1974 1) * = FILES AVAILABLE AT NLM ONLY. 2) + = CITATIONS WITH PUBLICATION YEAR OF 1976 OR EARLIER BUT ENTRY DATE OF 1977 OR 1978 ALSO INCLUDED. 3) THE BACKFILES ARE AVAILABLE ONLY THRU OFFSEARCH AT NLM AND SUNY 4) TOXBACK IS AVAILABLE ONLY THRU OFFSEARCH AT NLH. This publication, which is issued monthly, is not copyrighted and may be freely reproduced. Editor: Grace H. McCarn Direct inquiries to: Assistant Editors: Yvonne B. Scott MEDLARS Management Section Sharon I. Valley, Ph.D. National Library of Medicine 8600 Rockville Pike Technical Notes Editor: Carolyn B. Til ley Bethesda, Maryland 20014 301/496-6193 NLM TECHKICAL BULLETIN - JAN 79 TECHNICAL NOTES PLEASE QUERY THE ON-LINE NEWS FILES DAILY FDR SPECIAL NOTICES AND MESSAGES Whenever applicable, the headings of each Technical Note will include a reference to the section of the NLM Online Services Reference Manual which is considered nost relevant to the item being discussed (e.g., Manual 2.9). Users should keep in Bind that the item nay pertain to other sections of the Manual. MESH HEADINGS When entering either a MeSH heading or a text word which is OR TEXT WORDS also a coamand name, depress the space bar once before in- WHICH ARE ALSO putting the anbiguous heading/word: COMMANDS SS 1 /C? USER: FILES AID FILING The initial space is needed to distinguish the heading/word from the command without quotes. ELEMENTS Reminder: The commands nay not be used COMMAND while in OFFSEARCH. (Manual 4.9.4 and 5.2) FACT Fact sheets on HISTLINE (HISTORY OF MEDICINE), BIOETHICS SHEETS and HEALTH PLANNING & ADMIN data bases are included with this issue. ELHILL Reminder: Hours of operation for NLM and SUNY are: HOURS (Manual 1.7) NLM SUNY MONDAY 3 AM - 6 PM 8 AM - PM TUESDAY 3 AM - 9 PM 3 AM - PM WEDNESDAY 3 AM - 6 PM 8 AM - 9 PM THURSDAY 3 AM - 6 PM 8 AM - 9 PM FRIDAY 3 AM - 9 PM 8 AM - 6 PM Neither NLM nor SUNY are up on Saturdays or Sundays, All tines are Eastern Tine. Prime Tine Hours: 10 AM-11:30 AM, 1 PM-5 PM Non-Prime Hours: Before 10 AM, between 11:30-1:00, after 5 PM RTECS The RTECS File (Registry of Toxic Effects of Chemical Sub- (Manual 14.) stances) was regenerated at NLM to include a quarterly update on January 8, 1979. The total nunfaer of records is now 32,603. -3- NLM TECHNICAL BULLETIN - JAN 79 A new "toxic effect" phrase has been added and can be searched as EQUIVOCAL TUMORIGENIC AGENT(IX). One change has been made in the class of compound field; CARCINOGEN(CC) has been expanded to CARCINOGLN-NEOPLASTIGEN(CC) and must be searched as shown, with the hyphen. For search strategy assistance, please contact the Toxicology Information Program (301/496-1131). CANCERPROJ The CANCERPROJ file was updated on January 12, 1979. The (Manual 17.) total number of records is now 21,646. The update tag is 7812 (ED). An updated cumulated alphabetical listing of CANCERPROJ subject captions is available from MEDLARS Management Section. Please include an address label with your request. Please update your hierarchical subject caption listing with the following changes: NEW AND CHANGED CAPTIONS IN NUMERIC CODE SEQUENCE 038720100 T&B Cell Charact & Cooperation (CHANGED FROM) Lymphocytes and Lymphokines 038720200 T Cell Lymphokines & Mediators (CHANGED FROM) Macrophages and Phagocytosis 038720300 T&B Cell Surface Markers 038720400 T&B Cell Assays 038720500 T&B Cell Mitogens 038720600 T&B Cell, Other Activities 038720700 Macrophages & Phagocytosis 038720950 Other Cells (Ir) (CHANGED FROM) Other Effective with this update is a change in the PRINT FULL format. The following elements have been added: BD - BEGIN DATE ED - END DATE CLINPROT - Effective February 1, 1979, the following elements have (Manual 18.) been added to those which will be printed with the PRINT or PRINT STANDARD command: IR - INVESTIGATORS CD - CORRECTION DATE Also, the following element has been added to those which will print with the PRINT FULL command: CD - CORRECTION DATE PHONES Appendix A is an updated list of telecommunications phone numbers for accessing NLM and SUMY. .4- NLM TECHNICAL BULLETIN - 0AN 79 FERTILIZATION - FERTILIZATION IN VITRO Is now a Major descriptor in NeSH. IN VITRO Citations on in vitro fertilization which have already been input for 1979 will have FERTILIZATION IN VITRO added as an index tern. It is expected that SDILINE/MEDLINE will reflect this change with the April 79 update. FERTILIZATION IN VITRO E5.820.150.410 68.520.277.320 Fertilization of an egg outside the body when the egg is nornally fertilized in the body. only /drug eff /instrun /Methods /rad eff; do not check the tags IN VITRO, PREGNANCY or FEMALE X TEST TUBE BABIES (TEST TUBE BABIES, formerly an entry tern to ECTOGENESIS, is now an entry tera to FERTILIZATION IN VITRO. Citations on test tube babies already input for 1979 will be file Maintained to FERTILIZATION IN VITRO.) AVLINE UPDATE Linda Kudrick, Technical Services Division, NLM ENHANCEMENTS TO AVLINE As of February 1, AVLINE citations have been class updated to reflect the 1979 MeSH. There have also been several changes in the AVLINE data base which are designed to enhance search capabilities or to clarify existing Information. The new Online Services Reference Manual will reflect these changes. I. Rating tag The use of the tag HIGHLY RECOMMENDED has been relnstltuted. All titles re- viewed since 1976 which are described as highly recoMMended In the critical abstracts, but which were previously tagged RECOMMENDED are now searchable by HIGHLY RECOMMENDED (RD). II. Learning Method tags A. Beginning with titles reviewed in 1979. the tag SUPPORT replaces the tern LECTURE SUPPORT. Please note that for the present both tens should be used if full retrieval is desired. -5- NLM TECHNICAL BULLETIN - JAH 79 B. Continuing Education Credit tag All AVLINE titles which Indicate the availability of continuing education credit are now directly searchable through a new tag CE CREDIT (RO). A corresponding note detailing the specific type and muter of CE units for the title Is printable In a newly defined Continuing Education Credit Note (CR). This note prints automatically In the standard PRT and PRT DETAILED, but can also be added to any tailored print command. III. Audience level tags A. Two new audience level tags have been added for searching. They are: 1. NON-DEGREE/TECHNICAL Programs leading to a non-degree certificate as In In-house training, or in programs for Nurses' Aids, some physician assistant programs, emergency technician. 2. ADVANCE CERTIFICATE In allied health professions and In nursing education this may be advanced training having programs In specific area4, e.g., nurse practitioners, operating room nurses, etc. Search strategies are Identical to those used for UNDERGRADUATE, GRADUATE AND CONTINUING EDUCATION. Example: SS 1 /C? CATHETERIZATION AND NURSING (RD) AND NON-DEGREE/TECHNICAL (RD) B. Primary Audience Designator Many AVLINE titles are considered appropriate for more than one audience; however, beginning with titles reviewed In 1979, a primary audience will be designated by use of an asterisk (*) directly preceding the term. The asterisked term Is directly searchable In the RD field and will also appear In the General Notes field. SS 1 /C? USER: ANTIBIOTICS AND 'NURSING (RD) PROG: SS (1) PSTG (8) SS 2 /C? USER: PRT 1 TI.TC.GN.RD -6- HLM TECHNICAL BULLETIN - JAN 79 1 TI - AHTIBIOTICS/N TC - .
Recommended publications
  • Educational Paper Ciliopathies

    Educational Paper Ciliopathies

    Eur J Pediatr (2012) 171:1285–1300 DOI 10.1007/s00431-011-1553-z REVIEW Educational paper Ciliopathies Carsten Bergmann Received: 11 June 2011 /Accepted: 3 August 2011 /Published online: 7 September 2011 # The Author(s) 2011. This article is published with open access at Springerlink.com Abstract Cilia are antenna-like organelles found on the (NPHP) . Ivemark syndrome . Meckel syndrome (MKS) . surface of most cells. They transduce molecular signals Joubert syndrome (JBTS) . Bardet–Biedl syndrome (BBS) . and facilitate interactions between cells and their Alstrom syndrome . Short-rib polydactyly syndromes . environment. Ciliary dysfunction has been shown to Jeune syndrome (ATD) . Ellis-van Crefeld syndrome (EVC) . underlie a broad range of overlapping, clinically and Sensenbrenner syndrome . Primary ciliary dyskinesia genetically heterogeneous phenotypes, collectively (Kartagener syndrome) . von Hippel-Lindau (VHL) . termed ciliopathies. Literally, all organs can be affected. Tuberous sclerosis (TSC) . Oligogenic inheritance . Modifier. Frequent cilia-related manifestations are (poly)cystic Mutational load kidney disease, retinal degeneration, situs inversus, cardiac defects, polydactyly, other skeletal abnormalities, and defects of the central and peripheral nervous Introduction system, occurring either isolated or as part of syn- dromes. Characterization of ciliopathies and the decisive Defective cellular organelles such as mitochondria, perox- role of primary cilia in signal transduction and cell isomes, and lysosomes are well-known
  • Laboratory Safety Manual

    Laboratory Safety Manual

    LABORATORY SAFETY MANUAL Environment, Health & Safety 1120 Estes Drive Extension CB# 1650 TABLE OF CONTENTS Section or Chapter Page Introduction i Emergency Telephone Numbers ii EHS – Scope of Service iii Condensed Laboratory Safety Information for New Research Personnel v Chapter 1 – Laboratory Safety at the University of North Carolina at Chapel Hill 1-1 Chapter 2 – Laboratory Safety Plan 2-1 Chapter 3 – General Safety Principles and Practices 3-1 Chapter 4 – Proper Storage of Chemicals in Laboratories 4-1 Chapter 5 – Protective Clothing and Equipment 5-1 Chapter 6 – Safe Handling of Chemicals 6-1 Chapter 7 – Highly Toxic Chemicals and Select Carcinogens 7-1 Chapter 8 – Reproductive Health 8-1 Chapter 9 – Controlled Substances 9-1 Chapter 10 – Fire Safety 10-1 Chapter 11 – Explosive and Reactive Chemical Hazards 11-1 Chapter 12 – Management of Laboratory Wastes 12-1 Chapter 13 – Safe Handling of Peroxidizable Compounds 13-1 Chapter 14 – Safe Handling of Laboratory Animals 14-1 Chapter 15 – Safe Handling of Biological Hazards 15-1 Chapter 16 – Biological Safety Cabinets 16-1 Chapter 17 – Laboratory Hoods 17-1 Chapter 18 – Safe Use of Nanomaterials 18-1 Revisions to Laboratory Safety Manual REV-1 Laboratory Safety Manual – the University of North Carolina at Chapel Hill INTRODUCTION This manual is a safety reference document for laboratory personnel at the University of North Carolina at Chapel Hill. The University’s Department of Environment, Health & Safety prepared this manual, followed by review and approval from both the University’s Laboratory and Chemical Safety Committee (LCSC) and the University Safety and Security Committee (USSC).
  • Anticonvulsants

    Anticonvulsants

    ALZET® Bibliography References on the Administration of Anticonvulsive Agents Using ALZET Osmotic Pumps 1. Carbamazepine Q5784: K. Deseure, et al. Differential drug effects on spontaneous and evoked pain behavior in a model of trigeminal neuropathic pain. J Pain Res 2017;10(279-286 ALZET Comments: Carbamazepine, baclofen, clomipramine; DMSO, PEG, Ethyl Alcohol, Acetone; SC; Rat; 2ML1; Controls received mp w/ vehicle; animal info (7 weeks old); dimethyl sulfoxide, propylene glycol, ethyl alcohol, and acetone at a ratio of 42:42:15:1; post op. care (morphine 5 mg/day); behavioral testing (Facial grooming); Therapeutic indication (Trigeminal neuralgia, neuropathic pain); Dose (30 mg/day carbamazepine (the first-line drug treatment for trigeminal neuralgia), 1.06 mg/day baclofen, 4.18 mg/day clomipramine, and 5 mg/day morphine);. Q0269: S. M. Cain, et al. High resolution micro-SPECT scanning in rats using 125I beta-CIT: Effects of chronic treatment with carbamazepine. Epilepsia 2009;50(8):1962-1970 ALZET Comments: Carbamazepine; DMSO; propylene glycol; ethyl alcohol; acetone; SC; Rat; 2ML2; 14 days; Controls received mp w/ vehicle; animal info (adult, male, Sprague-Dawley, 160-270 g); functionality of mp verified by serum drug levels; 42% DMSO used; identified 3 mg/kg/day as the highest dose that could be reliably administered via minipumps over a 14-day period at 37 degrees Celsius, pg. 1969. P5195: H. C. Doheny, et al. A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy. British Journal of Pharmacology 2002;135(6):1425-1434 ALZET Comments: Carbamazepine; levetiracetam; DMSO; Propylene glycol; ethanol, saline; IP; Rat; 7 days; Controls received mp/ vehicle; functionality of mp verified by drug serum levels; dose-response (text p.1428); carbamazepine was dissolved in 42.5% DMSO/42% Propylene glycol/15% ethanol.
  • Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al

    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
  • Research Day 2021 Program

    Research Day 2021 Program

    Western Michigan University ScholarWorks at WMU Research Day WMU Homer Stryker M.D. School of Medicine 2021 Research Day 2021 Program Western Michigan University Homer Stryker M.D. School of Medicine Follow this and additional works at: https://scholarworks.wmich.edu/medicine_research_day Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons WMU ScholarWorks Citation Homer Stryker M.D. School of Medicine, Western Michigan University, "Research Day 2021 Program" (2021). Research Day. 298. https://scholarworks.wmich.edu/medicine_research_day/298 This Abstract is brought to you for free and open access by the WMU Homer Stryker M.D. School of Medicine at ScholarWorks at WMU. It has been accepted for inclusion in Research Day by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. th 38 Annual Kalamazoo Community Medical and Health Sciences Virtual Research Day Wednesday, April 21, 2021 8:00 a.m. – 12:00 p.m. TABLE OF CONTENTS INTRODUCTION ........................................................................................................... 4 KEYNOTE SPEAKER.................................................................................................... 6 SCHEDULE ..................................................................................................................... 7 ORAL PRESENTATIONS ............................................................................................. 8 ORAL ABSTRACTS ....................................................................................................
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • The Hns Gene of Escherichia Coli Is Transcriptionally Down-Regulated by (P)Ppgpp

    The Hns Gene of Escherichia Coli Is Transcriptionally Down-Regulated by (P)Ppgpp

    microorganisms Article The hns Gene of Escherichia coli Is Transcriptionally Down-Regulated by (p)ppGpp Anna Brandi, Mara Giangrossi, Attilio Fabbretti and Maurizio Falconi * School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy; [email protected] (A.B.); [email protected] (M.G.); [email protected] (A.F.) * Correspondence: [email protected]; Tel.: +39-0737-403274 Received: 25 August 2020; Accepted: 8 October 2020; Published: 10 October 2020 Abstract: Second messenger nucleotides, such as guanosine penta- or tetra-phosphate, commonly referred to as (p)ppGpp, are powerful signaling molecules, used by all bacteria to fine-tune cellular metabolism in response to nutrient availability. Indeed, under nutritional starvation, accumulation of (p)ppGpp reduces cell growth, inhibits stable RNAs synthesis, and selectively up- or down- regulates the expression of a large number of genes. Here, we show that the E. coli hns promoter responds to intracellular level of (p)ppGpp. hns encodes the DNA binding protein H-NS, one of the major components of bacterial nucleoid. Currently, H-NS is viewed as a global regulator of transcription in an environment-dependent mode. Combining results from relA (ppGpp synthetase) and spoT (ppGpp synthetase/hydrolase) null mutants with those from an inducible plasmid encoded RelA system, we have found that hns expression is inversely correlated with the intracellular concentration of (p)ppGpp, particularly in exponential phase of growth. Furthermore, we have reproduced in an in vitro system the observed in vivo (p)ppGpp-mediated transcriptional repression of hns promoter. Electrophoretic mobility shift assays clearly demonstrated that this unusual nucleotide negatively affects the stability of RNA polymerase-hns promoter complex.
  • United States Patent (19) (11) 4,310,524 Wiech Et Al

    United States Patent (19) (11) 4,310,524 Wiech Et Al

    United States Patent (19) (11) 4,310,524 Wiech et al. 45 Jan. 12, 1982 (54) TCA COMPOSITION AND METHOD FOR McMillen et al., Fed. Proc., 38,592 (1979). RAPD ONSET ANTDEPRESSANT Sellinger et al., Fed. Proc., 38,592 (1979). THERAPY Pandey et al., Fed. Proc., 38,592 (1979). 75) Inventors: Norbert L. Wiech; Richard C. Ursillo, Primary Examiner-Stanley J. Friedman both of Cincinnati, Ohio Attorney, Agent, or Firm-Millen & White 73) Assignee: Richardson-Merrell, Inc., Wilton, Conn. (57 ABSTRACT A method is provided for treating depression in a pa (21) Appl. No.: 139,498 tient therefrom and requiring rapid symptomatic relief, (22 Filed: Apr. 11, 1980 which comprises administering to said patient concur 51) Int. Cl. .................... A61K 31/33; A61K 31/135 rently (a) an effective antidepressant amount of a tricy clic antidepressant or a pharmaceutically effective acid (52) ...... 424/244; 424/330 addition salt thereof, and (b) an amount of an a-adrener 58) Field of Search ................................ 424/244, 330 gic receptor blocking agent effective to achieve rapid (56) References Cited onset of the antidepressant action of (a), whereby the PUBLICATIONS onset of said antidepressant action is achieved within Chemical Abst., vol. 66-72828m, (1967), Kellett. from 1 to 7 days. Chemical Abst, vol. 68-94371a, (1968), Martelli et al. A pharmaceutical composition is also provided which is Chemical Abst., vol. 74-86.048j, (1971), Dixit et al. especially adapted for use with the foregoing method. Holmberg et al., Psychopharm., 2,93 (1961). Svensson, Symp. Med. Hoechst., 13, 245 (1978). 17 Claims, No Drawings 4,310,524 1.
  • Développement D'hybrides Aptamère-Peptide

    Développement D'hybrides Aptamère-Peptide

    UNIVERSITÉ DU QUÉBEC INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE INSTITUT ARMAND-FRAPPIER DÉVELOPPEMENT D’HYBRIDES APTAMÈRE-PEPTIDE ANTIMICROBIEN UN MODÈLE POUR CIBLER DES BACTÉRIES PATHOGÈNES Par Amal Thamri Mémoire présenté pour l’obtention du grade de Maître en sciences (M.Sc.) en microbiologie appliquée Jury d’évaluation Examinateur externe: Dr. Roger.C Lévesque, Université de Laval Examinateur interne: Dr. Frédéric Veyrier, INRS-IAF Directeur de recherche: Dr. Jonathan Perreault, INRS-IAF Co-directrice de recherche: Dre. Annie Castonguay, INRS-IAF Remerciements Cette maîtrise a été réalisée dans le cadre d’une coopération entre INRS et le ministère d’enseignement supérieur tunisien. Les recherches objets de ce mémoire ont été réalisées dans différents laboratoires de l’institut Armand-Frappier: Laboratoires des professeurs: Jonathan Perreault, Annie Castonguay, Eric Déziel, David Chatenet. Je tiens à remercier toutes les personnes qui ont participé de près ou de loin au bon déroulement et à l’avancement des travaux de cette maîtrise. Je remercie spécialement mon directeur de recherche Jonathan Perreault pour avoir cru en mes capacités d’intégrer sa jeune équipe et travailler sur un projet novateur. Je remercie très sincèrement ma co-directrice Annie Castonguay pour ses encouragements tout au long de ces deux années. Je les remercie également d'avoir bien assuré la direction et l'encadrement de mes travaux de recherche. Merci au professeur Eric Déziel pour sa compréhension et ses conseils précieux. J’adresse aussi mes remerciements au professeur David Chatenet pour sa disponibilité, ses directions bénéfiques et ses remarques pertinentes. J’adresse mes sentiments de respect et de gratitude à Myriam Letourneau et Marie- Christine Groleau pour leur générosité et leur aide à mettre en place et améliorer plusieurs expériences.